Organization
SP Botkin Moscow City Clinical Hospital
1 abstract
Abstract
Phase 3 study results of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) versus VRd for transplant-ineligible patients with newly diagnosed multiple myeloma (IMROZ).Org: University of Lille, CHU Lille - Hopital Huriez, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Service d'Hématologie et Thérapie Cellulaire,